BLU-945 是一种有效的选择性表皮生长因子受体 (EGFR) 抑制剂。EGFR是erbB受体家族的成员，该家族包括跨膜蛋白酪氨酸激酶受体。BLU-945 有效抑制具有 L858R 和/或外显子 19 缺失突变、T790M 突变和 C797S 突变的 EGFR。BLU-945 有助于有效给药并降低 EGFR 介导的靶向毒性。BLU-945 具有研究癌症疾病的潜力 (信息提取自专利 WO2021133809A1，化合物 112)。
货号:ajcx36600
CAS:2660250-10-0
分子式:C28H37FN6O3S
分子量：556.7
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货
Background:
receptor (EGFR). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112)[1].
[1]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
动态评分
0.0